<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02707484</url>
  </required_header>
  <id_info>
    <org_study_id>rj(2015)088K-a</org_study_id>
    <nct_id>NCT02707484</nct_id>
  </id_info>
  <brief_title>the Efficiency of Thalidomide for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation</brief_title>
  <official_title>the Efficacy of Thalidomide for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation: a Prospective Multi-center Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastrointestinal vascular malformation (GIVM), which is an important cause of acute or
      chronic gastrointestinal bleeding, currently lacks of effective treatment. The investigators'
      previous study first confirmed thalidomide treatment of GIVM bleeding was safe and effective.
      This prospective multi-center randomized controlled clinical trial intends to investigate the
      efficacy of thalidomide to the recurrent small intestinal hemorrhage due to GIVM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multi-institutional clinical trial investigates the efficacy of thalidomide to the
      recurrent small intestinal hemorrhage due to GIVM. Patients with annual average bleeding 4
      times or more and lesions located in the small intestine which are not suitable for
      endoscopic therapy will be randomly assigned to receive A(25mg,Thalidomide，qid), B(25mg,
      Thalidomide, bid&amp; placebo bid ) or placebo(deferred treatment group) for 4 months. The
      primary endpoints were the difference in yearly bleeding Episodes, followed by the difference
      in Blood Transfusions, Total Transfused Red Cell Requirements, Bleeding Duration, yearly mean
      Hemoglobin (Hb) level, hospitalization and iron requirement. After one year follow-up, the
      treatment of 100mg thalidomide might be paid as supplementary therapy for non-responders if
      necessary. This study will be done at 10 centers in China.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants Whose yearly Rebleeding times Decreased From Baseline by ≥ 50%</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>The primary end point was defined as the patients whose rebleeds decreased from baseline by ≥ 50% at 12 months. Reduction of rebleeds = [(total bleeding episode at 12 months - total bleeding episodes at a year before randomization)/total bleeding episodes at a year before randomization(baseline)]*100%. Rebleeding was defined based on a positive fecal occult blood test (FOBT) (monoclonal colloidal gold color technology) at any visit after treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>difference of patients requiring Blood Transfusions</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>difference in Total Transfused Red Cell Requirements</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change from baseline in bleeding duration at 12 months</measure>
    <time_frame>baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>difference of average Hemoglobin (Hb) level yearly</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>difference of patients requiring hospitalization</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>difference of yearly hospitalization times</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>difference of the number of days in hospital yearly</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentual reduction in iron requirement</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of patients completely cured</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Gastrointestinal Vascular Malformation</condition>
  <arm_group>
    <arm_group_label>Thalidomide Group（100mg）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Thalidomide Group（50mg）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo -controlled Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide (100mg)</intervention_name>
    <description>Patients were randomly assigned to receive a four-month course of 100 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).</description>
    <arm_group_label>Thalidomide Group（100mg）</arm_group_label>
    <other_name>Group 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide (50mg)</intervention_name>
    <description>Patients were randomly assigned to receive a four-month course of 50 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).</description>
    <arm_group_label>Thalidomide Group（50mg）</arm_group_label>
    <other_name>Group 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Patients were randomly assigned to receive a four-month course of placebo (Pharmaceutical Co., Ltd. of ChangZhou, China).</description>
    <arm_group_label>placebo -controlled Group</arm_group_label>
    <other_name>Group 3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patients should sign informed consent and be informed of the specific trial plan;

          -  The patients should have the China nationality;

          -  The patients should be aged from 18 to 70 years old, male or female; Patients must
             agree to follow acceptable birth control such as physical intrauterine contraceptive
             ring or use a condom. Female with the potential for pregnancy need to have a negative
             serum or urine pregnancy test prior to treatment.

          -  The intestinal vascular lesions should be found by capsule endoscopy, and / or balloon
             assisted enteroscopy; OR the patients should present with persistent and recurrent
             bleeding, while the bleeding lesions are unable to be located after initial negative
             results on endoscopic evaluation by upper GI endoscopy, colonoscopy and CTE;

          -  The patients should present with persistent and recurrent bleeding (&gt;=4 times yearly);

          -  Hb levels should decreased 10% lower than baseline；

          -  The patient is willing to comply with the instructions and have the ability to
             complete the study of research program.

        Exclusion Criteria:

          -  patients associated with varicosity due to cirrhosis of the liver; Or patients with
             uncontrolled hypertension, uncontrolled hyperglycemia, or other severe diseases;

          -  patients with a history of severe peripheral neuropathy, seizures, rheumatoid immune
             disease, or thromboembolic disease;

          -  patients with indications which should constantly use non-steroidal anti-inflammatory
             drugs, anticoagulants and antiplatelet or acetyl salicylic acid preparation, ginkgo,
             Echinacea, Chinese herbal medicine composition, other anti-angiogenesis drugs;

          -  patients with malignant or severe heart disease (uncontrolled angina and/or myocardial
             infarction, congestive heart failure within 3 months before recruiting, etc.), lung
             disease (respiratory failure), kidney (Cr, BUN 2 times more than normal ceiling),
             pancreatic, liver disease(severe liver function damage 2 times more than normal ALT,
             AST, TBIL cap) or other diseases that researchers evaluated as affect the judgment of
             the treatment;

          -  sustained WBC &lt;3.5 * 109 / L;

          -  previously small intestinal bowel resection surgery;

          -  patients are known or suspected allergic to any ingredient to thalidomide;

          -  serious life-threatening gastrointestinal bleeding requiring immediate surgical
             treatment;

          -  patients have used the study drug within 30 days before recruiting;

          -  alcohol and/or drug abuse, addiction or rely on) or the doctor determine compliance
             claim;

          -  patients had been recruited into other clinical research within 6 months;

          -  personnel related to this study;

          -  patients have no legal behavior ability or self-knowledge; Or patients refuse into
             groups.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhizheng Ge, MD, Ph D</last_name>
    <email>zhizhengge@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yan Xuemin</last_name>
      <phone>18612247293</phone>
      <email>pumchyxm@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinqiao Hospital of Chongqing</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xie Xia</last_name>
      <phone>13452166767</phone>
      <email>xiexia@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital of Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Li Yue</last_name>
      <phone>15975537291</phone>
      <email>liyue_1989919@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liu li</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fan Rong</last_name>
      <phone>13661757972</phone>
      <email>rong_de_fan@yahoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shen Xizhong</last_name>
      <phone>13877783888</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhong Liang</last_name>
      <phone>13901657183</phone>
      <email>zhongniping@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200092</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu Leiming</last_name>
      <phone>13651686398</phone>
      <email>LeiMing.Xu@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Gastroenterology, Renji Hospital, Shanghai Institute of Digestive Diseases, Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhizheng Ge, MD. Ph.D</last_name>
      <phone>18621890923</phone>
      <email>zhizhengge@aliyun.com.cn</email>
    </contact>
    <investigator>
      <last_name>Zhizheng Ge, MD. Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wang Dong</last_name>
      <phone>13817655762</phone>
      <email>dr.dongwang@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201620</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lu Lungen</last_name>
      <phone>13381616206</phone>
      <email>lungenlu1965@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Ge ZZ, Chen HM, Gao YJ, Liu WZ, Xu CH, Tan HH, Chen HY, Wei W, Fang JY, Xiao SD. Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. Gastroenterology. 2011 Nov;141(5):1629-37.e1-4. doi: 10.1053/j.gastro.2011.07.018. Epub 2011 Jul 22.</citation>
    <PMID>21784047</PMID>
  </results_reference>
  <results_reference>
    <citation>Ge ZZ, Chen HY, Gao YJ, Hu YB, Xiao SD. Best candidates for capsule endoscopy for obscure gastrointestinal bleeding. J Gastroenterol Hepatol. 2007 Dec;22(12):2076-80.</citation>
    <PMID>18031363</PMID>
  </results_reference>
  <results_reference>
    <citation>Tan H, Chen H, Xu C, Ge Z, Gao Y, Fang J, Liu W, Xiao S. Role of vascular endothelial growth factor in angiodysplasia: an interventional study with thalidomide. J Gastroenterol Hepatol. 2012 Jun;27(6):1094-101. doi: 10.1111/j.1440-1746.2011.06967.x.</citation>
    <PMID>22098296</PMID>
  </results_reference>
  <results_reference>
    <citation>Li XB, Ge ZZ, Dai J, Gao YJ, Liu WZ, Hu YB, Xiao SD. The role of capsule endoscopy combined with double-balloon enteroscopy in diagnosis of small bowel diseases. Chin Med J (Engl). 2007 Jan 5;120(1):30-5.</citation>
    <PMID>17254484</PMID>
  </results_reference>
  <results_reference>
    <citation>Tan HH, Ge ZZ, Gao YJ, Chen HM, Fang JY, Chen HY, Liu WZ, Xiao SD. The role of HIF-1, angiopoietin-2, Dll4 and Notch1 in bleeding gastrointestinal vascular malformations and thalidomide-associated actions: a pilot in vivo study. J Dig Dis. 2011 Oct;12(5):349-56. doi: 10.1111/j.1751-2980.2011.00506.x.</citation>
    <PMID>21955427</PMID>
  </results_reference>
  <results_reference>
    <citation>Feng Q, Tan HH, Ge ZZ, Gao YJ, Chen HM, Xiao SD. Thalidomide-induced angiopoietin 2, Notch1 and Dll4 downregulation under hypoxic condition in tissues with gastrointestinal vascular malformation and human umbilical vein endothelial cells. J Dig Dis. 2014 Feb;15(2):85-95. doi: 10.1111/1751-2980.12114.</citation>
    <PMID>24219762</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2015</study_first_submitted>
  <study_first_submitted_qc>March 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2016</study_first_posted>
  <last_update_submitted>July 30, 2016</last_update_submitted>
  <last_update_submitted_qc>July 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Zhizheng Ge</investigator_full_name>
    <investigator_title>Director of digestive endoscopy center of Renji hospital</investigator_title>
  </responsible_party>
  <keyword>Gastrointestinal vascular malformation</keyword>
  <keyword>thalidomide</keyword>
  <keyword>Small intestinal bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Vascular Malformations</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

